GLP-1 patches represent a newer option that provides transdermal delivery, though evidence for their effectiveness compared to injections is still limited
At day 85 (approximately 12 weeks), patients in the low-dose group lost an average of 7.19 percent of their body weight and the high-dose group lost an average of 14.52 percent of their body weight, while the placebo group gained an average of 1.49 percent of their body weight
Potential Demand for GLP-1s According to the Centers for Disease Control (CDC), in 2021, 29.4 million adults in the United States were diagnosed with diabetes (90 to 95 percent were T2D)
However, an increasing number of research studies are demonstrating that these substances also have neuroprotective effects in neurodegenerative diseases, mental disorders, and other brain conditions
Jeibmann, A., Alves, M., Rago, V., et al
including prescribing and dispensing medication (indicates whether the patient picked up the medication) trends
